Laboratoire Bailly Creat Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Laboratoire Bailly Creat Pharmaceutical Import Records from India — 2 Products, $908.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Laboratoire Bailly Creat — Pharmaceutical Importer Profile (2026) | 2 Products, $908.7K Trade | TransData Nexus

Laboratoire Bailly Creat

Pharmaceutical Importer · France · Advanced Antibiotics Focus · $908.7K Total Trade · DGFT Verified

Laboratoire Bailly Creat is a pharmaceutical importer based in France with a total trade value of $908.7K across 2 products in 1 therapeutic categories. Based on 40 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Laboratoire Bailly Creat sources from 2 verified Indian suppliers, with Medreich Limited accounting for 87.1% of imports.

Laboratoire Bailly Creat — Import Portfolio & Supplier Network

Laboratoire Bailly Creat import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Laboratoire Bailly Creat?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medreich Limited	$1.6M	56	87.1%
Ipca Laboratories Limited	$235.8K	6	12.9%

Laboratoire Bailly Creat sources from 2 verified Indian suppliers across .

What Formulations Does Laboratoire Bailly Creat Import?

Formulation	Value	Ships
Sulfamethoxazole and trimethoprim	$175.8K	7
Harmless medicines:paracetamol tablets	$100.0K	2
Paracetamol 500MG tablets 100x10s	$100.0K	2
Paracetamol 500MG tablets 100x10s	$65.5K	2
Paracetamol 500MG tablets 100x10s	$64.1K	2
Paracetamol 500MG tablets 100x12s (2456 packs)	$56.7K	2
Paracetamol 500MG tablets 100x10s	$50.0K	1
Paracetamol 500MG tablets 100x10s	$50.0K	1
Paracetamol 500MG tablets 100x10s 5862	$50.0K	1
Harmless medicines:paracetamol tablets 500mgparacetamol tablets 500mg18612x100x10's Pack =18612000	$50.0K	1
Harmless medicines:paracetamol tablets 500mgparacetamol tablets 500mg22374x100x10's Pack =22374000	$50.0K	1
Paracetamol 500MG tablets 100x10s (7733 packs)	$50.0K	1
Paracetamol 500MG tablets 100x10s (5812 packs)	$50.0K	1
Paracetamol 500MG tablets 100x10s (7379 packs)	$50.0K	1
Paracetamol 500MG tablets 100x10s (4375packs)	$42.7K	1

Laboratoire Bailly Creat imports 51 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Sulfamethoxazole	Advanced Antibiotics	$454.4K	20	2.3%	9
2	Trimethoprim	Advanced Antibiotics	$454.4K	20	1.7%	11

Laboratoire Bailly Creat imports 2 pharmaceutical products across 1 categories into France totaling $908.7K.

Laboratoire Bailly Creat — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Laboratoire Bailly-Creat is a French pharmaceutical company specializing in the manufacture and distribution of generic medicines and parapharmaceutical products. Established in 1908, the company has a longstanding history in the pharmaceutical industry. It is headquartered in Vernouillet, Eure-et-Loir, France, at Chemin de Nuisement, Z.I. des 150 Arpents – B.P. 50017, 28509 Vernouillet cedex.

The company produces and distributes its products in over thirty countries, with a particular focus on markets in Africa, the Middle East, and Asia. Laboratoire Bailly-Creat is privately held and employs between 51 and 200 people. In 2021, the company reported a net revenue of €23,129,570. (journal-economique.fr)

2Distribution Network

Laboratoire Bailly-Creat's distribution network is centered around its manufacturing facility in Vernouillet, France. The company markets and distributes its products globally, with a significant presence in Africa, the Middle East, and Asia. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive international reach suggests a well-established distribution infrastructure capable of supporting its global operations.

3Industry Role

Laboratoire Bailly-Creat operates as a pharmaceutical manufacturer and distributor, focusing on the production of generic medicines and parapharmaceutical products. The company is not a wholesaler, parallel importer, hospital supplier, or logistics intermediary. Its role in France's pharmaceutical supply chain is that of a producer and exporter, supplying generic pharmaceutical products to various international markets.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Laboratoire Bailly Creat

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Laboratoire Bailly-Creat's sourcing strategy appears to be highly concentrated, with a significant portion of its imports from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations worth $909,000 USD from India, comprising 40 shipments. The top two products imported were Sulfamethoxazole and Trimethoprim, each valued at $454,000 USD, accounting for 2.3% and 1.7% of the total import value, respectively. Both products fall under the Advanced Antibiotics therapeutic category, indicating a strategic focus on this segment.

The supplier concentration is also notable, with two primary suppliers: MEDREICH LIMITED, accounting for 87.1% of the shipments, and IPCA LABORATORIES LIMITED, comprising 12.9%. This suggests a strong reliance on these suppliers for the company's antibiotic formulations. The high concentration could pose risks related to supply chain disruptions or changes in supplier dynamics. However, it may also reflect strategic partnerships aimed at ensuring consistent quality and supply.

2Supply Chain Resilience

Laboratoire Bailly-Creat's supply chain resilience concerning its Indian suppliers appears to be moderate. The company imports a diverse range of 51 unique formulations, indicating a broad product portfolio. However, the heavy reliance on two suppliers for its antibiotic formulations suggests potential vulnerabilities. The absence of backup suppliers for these critical products could expose the company to risks if any disruptions occur with MEDREICH LIMITED or IPCA LABORATORIES LIMITED. Additionally, the company's shipping routes and regulatory compliance of key suppliers are not publicly detailed, making it challenging to fully assess the resilience of the supply chain.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the French National Agency for Medicines and Health Products Safety (ANSM). The ANSM is responsible for ensuring the safety, efficacy, and quality of health products available in France. Key legislation governing pharmaceutical imports includes the Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of medicinal products.

For Indian generics to be marketed in France, they must undergo a marketing authorization process, which can be obtained through the European Medicines Agency (EMA) or via national procedures. The EMA provides centralized marketing authorizations valid across all EU member states, while national procedures are specific to individual countries. The marketing authorization pathway involves rigorous evaluation of the product's quality, safety, and efficacy data.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France are stringent. Importers must hold a wholesale distribution authorization issued by the ANSM, which ensures compliance with Good Distribution Practice (GDP) standards. Additionally, the imported products must be manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards recognized by the European Union, the World Health Organization (WHO), or the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This ensures that the products meet the necessary quality standards for the French market.

Laboratoire Bailly Creat — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Laboratoire Bailly-Creat's focus on advanced antibiotics, particularly Sulfamethoxazole and Trimethoprim, aligns with the ongoing demand for effective treatments against bacterial infections. The global rise in antibiotic resistance underscores the need for accessible and effective antibiotics, driving the importation of these products. By concentrating on this therapeutic area, the company positions itself to meet a critical healthcare need, ensuring a steady market demand for its products.

2Sourcing Profile

Laboratoire Bailly-Creat's sourcing strategy emphasizes the procurement of generic drugs, with a particular focus on antibiotic formulations. The company's reliance on Indian suppliers, such as MEDREICH LIMITED and IPCA LABORATORIES LIMITED, reflects India's strong position in the global generic pharmaceutical market. This approach allows the company to offer cost-effective products while maintaining quality standards. India's compliance with international GMP standards further supports this sourcing strategy.

3Market Positioning

Based on its product mix, Laboratoire Bailly-Creat primarily serves the wholesale distribution segment of the French market. By importing and distributing generic antibiotics, the company supplies these essential medicines to various healthcare providers, including hospitals, clinics, and pharmacies. Its focus on advanced antibiotics positions it as a key player in addressing the healthcare needs related to bacterial infections in France.

Seller's Guide — How to Become a Supplier to Laboratoire Bailly Creat

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Laboratoire Bailly-Creat's supply chain. The company's reliance on a limited number of suppliers for its antibiotic formulations suggests potential for diversification. Indian exporters who can meet the required quality standards, offer competitive pricing, and ensure reliable delivery could establish partnerships with Laboratoire Bailly-Creat. Additionally, the company's focus on advanced antibiotics indicates a sustained demand for these products, presenting a stable market opportunity.

2Requirements & Qualifications

Indian exporters aiming to supply Laboratoire Bailly-Creat must ensure that their manufacturing facilities comply with GMP standards recognized by the EU, WHO, or PIC/S. Products must undergo batch testing and stability studies to meet French regulatory requirements. Labeling must be in French, providing comprehensive product information. Additionally, exporters should be prepared to adhere to serialization mandates to ensure product traceability and prevent counterfeiting.

3How to Approach

Frequently Asked Questions — Laboratoire Bailly Creat

What products does Laboratoire Bailly Creat import from India?

Laboratoire Bailly Creat imports 2 pharmaceutical products across 1 categories. Top imports: Sulfamethoxazole ($454.4K), Trimethoprim ($454.4K).

Who supplies pharmaceuticals to Laboratoire Bailly Creat from India?

Laboratoire Bailly Creat sources from 2 verified Indian suppliers. The primary supplier is Medreich Limited (87.1% of imports, $1.6M).

What is Laboratoire Bailly Creat's total pharmaceutical import value?

Laboratoire Bailly Creat's total pharmaceutical import value from India is $908.7K, based on 40 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Laboratoire Bailly Creat focus on?

Laboratoire Bailly Creat imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Laboratoire Bailly Creat Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.